Related Experiment Videos
Oral cytembena absorption and phase I--II studies
Cancer Treatment Reports
|March 1, 1978
Summary
Cytembena shows excellent oral absorption and a short half-life, suggesting new administration methods are needed. Dose-limiting toxic effects from oral administration include transient proteinuria and increased creatinine levels.
Area of Science:
- Pharmacology
- Oncology
- Drug Development
Background:
- Cytembena is a nonmyelosuppressive chemotherapeutic agent used in Europe.
- Phase I-II trials have been conducted in the United States.
- Current administration routes have dose-limiting toxic effects.
Purpose of the Study:
- To evaluate alternative routes and schedules for Cytembena administration.
- To investigate the pharmacokinetic profile of Cytembena.
- To identify dose-limiting toxic effects of oral Cytembena.
Main Methods:
- The study reports on the oral absorption and half-life of Cytembena.
- It also details toxic effects observed after frequent oral administration.
Main Results:
- Cytembena demonstrates excellent oral absorption.
- The drug has a short plasma half-life.
- Transient proteinuria and increased creatinine levels were identified as dose-limiting toxic effects of oral administration.
Conclusions:
- Alternative routes and schedules for Cytembena administration should be explored.
- Oral administration may offer a viable alternative if toxicities are managed.
- Further research is needed to optimize Cytembena's therapeutic index.